Table 1.
Baseline demographic and disease characteristics
| Characteristic | Regimen A, N = 34 | Regimen B, N = 32 | Total, N = 66 |
|---|---|---|---|
| Age (years) | |||
| Median (range) | 62.5 (36–83) | 57.0 (36–72) | 59 (36–83) |
| Gender, n (%) | |||
| Male | 19 | 18 | 37 |
| Female | 15 | 14 | 29 |
| Race, n (%) | |||
| Asian | 17 (50%) | 29 (91%) | 46 (69%) |
| Black | 3 (9%) | 0 | 3 (5%) |
| White | 14 (41%) | 3 (9%) | 17 (26%) |
| Tumor type, n (%) | |||
| Breast | 10 (29%) | 17 (53%) | 27 (41%) |
| Gastroesophageal | 12 (35%) | 8 (25%) | 20 (30%) |
| Colorectal | 5 (15%) | 0 | 5 (8%) |
| Gall Bladder | 0 | 2 (11%) | 2 (3%) |
| Lung | 2 (6%) | 0 | 2 (3%) |
| Othera | 5 (15%) | 5 (28%) | 10 (15%) |
| ECOG status, n (%) | |||
| 0 | 16 (47%) | 13 (72%) | 38 (58%) |
| 1 | 18 (53%) | 5 (28%) | 28 (42%) |
| HER 2 expression, n (%) | |||
| Positive (IHC 3+) | 16 (47%) | 23 (72%) | 39 (59%) |
| Positive (IHC 2+, FISH amplified) | 1 (3%) | 3 (9%) | 4 (6%) |
| Negative (IHC 0 or IHC, FISH non-amplified) | 17 (50%) | 6 (19%) | 23 (35%) |
| Number of prior chemotherapy regimens | |||
| Median (range) | 3 (1–7) | 3 (1–7) | 3.0 (1–7) |
| Prior anti-HER2 therapy, n (%) | |||
| Any | 19 (56%) | 26 (81%) | 45 (68%) |
| Trastuzumab | 15 (44%) | 25 (78%) | 40 (61%) |
| Lapatinib | 13 (38%) | 15 (47%) | 28 (42%) |
| Other | 7 (21%) | 6 (19%) | 15 (23%) |
a
Other tumors include rectal, sigmoid colon, ampulla of Vater, bladder, endometrial cancer, esophageal-squamous cell carcinoma, malignant tumor of lacrimal gland, salivary duct cancer, submandibular gland cancer, and transitional cell carcinoma of the renal pelvis.